Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates

Key Takeaways Sarepta reported a Q4 loss of $3.58 per share as Elevidys sales plunged over 71% year over year.SRPT revenues fell 33% to $442.9M, but still beat estimates on higher collaboration income.Sarepta guided 2026 net product revenues of $1.2B-$1.4B and targets $800M-$900M in expenses.Sarepta Therapeutics, Inc. (SRPT) reported a fourth-quarter 2025 adjusted loss of $3.58 per share, wider than the Zacks Consensus Estimate of a loss of 71 cents. This higher-than-anticipated loss was attributed to an in ...